Article By:
Shock Exchange
Wednesday, October 4, 2017 6:29 PM EDT
A manhunt is on for the next dry-eye disruptor. RGRX and ALDX are two candidates. RGRX just completed Phase 3 testing. Its drug has shown success in head-to-head comparisons with Restasis and Xiidra. Will RGRX hit the dry-eye jackpot?
